The goal of this clinical trial is to learn the differences severity level of diabetic neuropathy based on electromyelography in type II diabetic patient with and without comorbidities. The main questions of this study: 1. What is the electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 2. Is there any differences in electromyography result in type II diabetic patient who: has no comorbidities, with hypertension, with hypertension and dyslipidemia? 3. Is there any association between distal latency with nerve conduction velocity in type II diabetic patient with and without comorbidities? 4. Is there any association between distal latency with amplitude in type II diabetic patient with and without comorbidities? 5. Is there any differences on diabetic neuropathy severity based on age, height, and A1C levels in type II diabetic patient with and without comorbidities? Researchers will collect information based on hospital registry as secondary data of in type II diabetic patient with and without comorbidities. The data consist of demographic data, clinical presentation, laboratory, and electromyography were collected from hospital registry by reviewing medical record. Then, the data was analyzed by using IBM SPSS Statistics v26.
Study Type
OBSERVATIONAL
Enrollment
78
All of groups will have assessment of electromyography result
Dr. Kariadi Central General Hospital
Semarang, Central of Java, Indonesia
Distal Latency
Distal latency defined as time between stimuli until deflection of Compound Muscle Action Potentials (CMAP) from baseline
Time frame: Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear
Nerve Conduction Velocity
Nerve Conduction Velocity defined as the measurement of axon conduction velocity by dividing space of nerve conduction with time needed
Time frame: Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear
Amplitude
Amplitude define as the height of first negative deflection of Compound Muscle Action Potentials (CMAP) from baseline
Time frame: Electromyography examination was done approximately 1 year after clinical onset of neuropathy appear
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.